Forum Financial Management LP Sells 1,935 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Forum Financial Management LP decreased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 10.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 16,183 shares of the company’s stock after selling 1,935 shares during the quarter. Forum Financial Management LP’s holdings in Teva Pharmaceutical Industries were worth $271,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. Cambridge Investment Research Advisors Inc. grew its stake in shares of Teva Pharmaceutical Industries by 97.5% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 84,263 shares of the company’s stock worth $1,295,000 after acquiring an additional 41,600 shares during the period. Golden State Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $39,000. Sequoia Financial Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 16.7% in the 1st quarter. Sequoia Financial Advisors LLC now owns 132,752 shares of the company’s stock worth $2,040,000 after purchasing an additional 18,955 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company’s stock worth $96,078,000 after purchasing an additional 5,186,592 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Teva Pharmaceutical Industries by 5.7% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock worth $38,487,000 after purchasing an additional 134,705 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $18.95 on Monday. The business’s 50-day moving average price is $19.08 and its two-hundred day moving average price is $17.31. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The stock has a market cap of $21.73 billion, a P/E ratio of -118.41, a PEG ratio of 1.04 and a beta of 0.71. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analysts’ expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company’s revenue was up .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Friday, October 3rd. UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Buy” and an average price target of $25.57.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at $102,693.84. The trade was a 47.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.